In addition, MORC4 recruits STAT3 to the MID2 promoter and drives MID2 expression in luminal A/B breast cancer cells, which enhances the chemoresistance of breast cancer, indicating that MORC4 may be a therapeutic target for luminal A/B breast cancer therapy [50]. The gene discussed is STAT3; the disease is breast carcinoma.